Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 09, 2023 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present at Two Investor Conferences in November

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that...
October 31, 2023 16:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Presents Preclinical Data Demonstrating Strong Efficacy and Favorable Safety Profile of REX-7117 Versus TYK2 and JAK Inhibitors at the Dermatology Drug Development Summit

- REX-7117 found to have superior efficacy to a clinically-relevant dose of deucravacitinib in a preclinical model of psoriasis - REX-7117, as a highly selective STAT3 inhibitor, demonstrates...
October 17, 2023 16:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Presents Preclinical Data from its STAT3 Inhibitor Program at the International Conference of the Inflammation Research Association (IRA)

- Pioneering compounds believed to be the first orally administered reversible inhibitors to bind to and inhibit the SH2 domain potently and selectively - Proprietary STAT3 inhibitors are...
August 30, 2023 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Participate in Multiple Investor Conferences in September

SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that...
July 20, 2023 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications

- Recludix to receive $125 million in near-term payments and potentially more than $1.2 billion subject to future milestones, and up to double-digit royalties on sales - - Recludix to lead research...
March 07, 2023 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference

SAN DIEGO, March 07, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that...
February 01, 2023 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present at the Guggenheim Healthcare Talks Oncology Conference

SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that...
January 06, 2023 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced that...
October 20, 2022 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Announces the Appointment of Accomplished Immunologist and Pharmacologist Paul A. Smith, Ph.D., as Senior Vice President of Biology

SAN DIEGO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced...
September 29, 2022 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Announces the Appointment of Senior Executive Matthew S. Caldemeyer as Chief Business Officer

SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the...